CVKD

Cadrenal Therape

• PUBT·3d ago

  Cadrenal Therapeutics to present at Lytham Partners Spring 2026 Investor Conference

• Seeking Alpha·05/07 14:40

  Cadrenal Therapeutics reports Q1 results

• Benzinga·05/07 13:00

  Cadrenal Therapeutics Q1 EPS $(1.04) Beats $(1.62) Estimate

• PUBT·05/07 12:34

  Cadrenal Q1 net loss narrows 35.1% to $2.5 million

• Dow Jones·05/07 12:32

  *Cadrenal Therapeutics 1Q Loss/Shr $1.04 >CVKD

• Dow Jones·05/07 12:32

  *Cadrenal Therapeutics 1Q Research and Development Expenses $771,508 >CVKD

• Reuters·05/07 12:30

  CADRENAL THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES PHASE 3 DEVELOPMENT UPDATE ON CAD-1005 FOLLOWING END-OF-PHASE 2 MEETING WITH FDA

• Dow Jones·05/07 12:30

  Press Release: Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

• TipRanks·05/01 13:51

  Analysts’ Top Healthcare Picks: Pacira Pharmaceuticals (PCRX), Cadrenal Therapeutics, Inc. (CVKD)

• TipRanks·05/01 13:50

  Noble Financial Reaffirms Their Buy Rating on Cadrenal Therapeutics, Inc. (CVKD)

• TipRanks·04/30 14:51

  Analysts Are Bullish on Top Healthcare Stocks: Cartesian Therapeutics (RNAC), Cadrenal Therapeutics, Inc. (CVKD)

• TipRanks·04/30 13:59

  Cadrenal Therapeutics completes CAD-1005 End-of-Phase 2 meeting with FDA

• TipRanks·04/30 13:49

  Cadrenal Advances CAD-1005 Into FDA-Guided Phase 3 Trial

• PUBT·04/30 12:39

  Cadrenal plans pivotal Phase 3 trial of CAD-1005 in heparin-induced thrombocytopenia

• Benzinga·04/30 12:37

  Cadrenal Therapeutics Receives FDA Guidance For Phase 3 Trial Of CAD-1005 Heparin-Induced Thrombocytopenia Treatment